Autoinflammatory & rare systemic diseases
The administration of methotrexate in patients with Still's disease, “real-life” findings from AIDA Network Still Disease Registry
Authors' conclusion
Clinical characteristics of patients with Still's disease treated with MTX were described, mainly joint features and fever without a prominent multiorgan involvement. The clinical usefulness of MTX was reported in reducing the disease activity, decreasing the inflammatory markers, and as GC-sparing agent.
Study context
- Population
- Patients with Still's disease treated with methotrexate (MTX) in the AIDA Network Still Disease Registry (males 43.3%, age 37.1 ± 16.0 years)
- Participants
- 171 patients
- Outcome
- Effectiveness of MTX: change in disease activity (modified systemic score) and clinical remission at end of follow-up
- Follow-up
- End
Methodological detailsmulticentre registry (AIDA Network Still Disease Registry), real-life, MTX given with glucocorticoid (GCs) in 68.4%, with other csDMARDs in 6.4%, with bDMARDs in 25.1%
- Multicentre registry (AIDA Network Still Disease Registry)
- Real-life
- MTX given with GCs in 68.4%, with other csDMARDs in 6.4%, with bDMARDs in 25.1%
Main finding
As reported in the abstract
Patients in clinical remission at end of follow-up
38.6%
Observational data: associations, not effects.
Safety
MTX discontinuation
- Because of adverse effects
- 12.3%
- For lack of efficacy
- 12.3%
Original publication
The administration of methotrexate in patients with Still's disease, “real-life” findings from AIDA Network Still Disease Registry. Semin Arthritis Rheum. Published 21 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →